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The magnitude and duration of acute inflammation
are controlled by active resolution programs involv-
ing specialized proresolving mediators (SPMs; resol-
vins and maresins) and microRNAs (miRNAs). Here,
we report that miR-466l was temporally regulated in
murine exudate-infiltrating leukocytes. Neutrophil
miR-466l overexpression in vivo promoted initiation
of inflammation that anteceded macrophage expres-
sion of this miRNA, which accelerated resolution
when overexpressed. In macrophages, miR-466l
overexpression increased prostanoids and SPMs
(e.g., resolvin D1 [RvD1] and RvD5), which enhanced
resolution. RvD1, RvD2, maresin 1 (MaR1), and
apoptotic neutrophils reduced miR-466l expression
within human macrophages, a feedback regulation
that most likely prepares for homeostasis. miR-466l
was upregulated in peripheral blood of sepsis
patients, and its increase correlated with nonsurvival
from sepsis. SPMs andmiR-466l regulated transcrip-
tion factors activator protein 1 and nuclear factor kB1
in miRNA biogenesis. These results demonstrate
pivotal roles for SPMs and miR-466l in dynamic
leukocyte plasticity during resolution of acute inflam-
matory responses.
INTRODUCTION
The acute inflammatory response is host protective, and its ideal
outcome is timely resolution (Serhan and Savill, 2005). By defini-
tion, an exudate contains fluid, cells, and cellular debris from
blood vessels deposited in tissues as a result of inflammation,
e.g., pus. Several families of lipid mediators (LMs) have been
uncovered with the use of self-limited inflammatory leukocyte-
rich exudates and a systems approach (Serhan, 2007). These
LMs have been coined specialized proresolving mediators
(SPMs), which include lipoxins (LXs), resolvins (Rvs), protectins,
andmaresins (MaRs). These are biosynthesized by inflammatory
exudates and possess unique structures with potent anti-Iinflammatory (e.g., limiting further polymorphonuclear neutrophil
[PMN] infiltration) and proresolving (e.g., enhancingmacrophage
clearance of microbial particles and apoptotic cells) actions, as
well as regulate microRNAs (miRNAs) involved in resolution
(Recchiuti et al., 2011).
Monocyte and macrophage lineage displays high plasticity
and pivotal roles in inflammation (Gordon, 2007; Serhan and
Savill, 2005). Upon exposure to stimuli, these cells undergo
classical proinflammatory M1 or alternative, anti-inflammatory
M2 differentiation (Sica and Mantovani, 2012). A third macro-
phage subset identified during the resolution phase of
self-limited inflammation has been coined resolution-phase
macrophages, which display an intermediate phenotype
(Bystrom et al., 2008; Russell and Gordon, 2009). Transcriptomic
profiling has shown that they are enriched with 15-LOX-1, key in
SPM biosynthesis (Stables et al., 2011). We previously reported
that SPMs stimulate polarization toward an M2-like profile
(Schif-Zuck et al., 2011; Titos et al., 2011), identified miRNAs
(i.e., miR-146b, miR-219, miR-208a, and miR-21) critical in
resolution, and established RvD1-receptor-dependent resolu-
tion circuits (Recchiuti et al., 2011).
These findings led us to question the underlying mechanisms
involving SPMs and miRNAs that regulate leukocyte plasticity
during resolution of inflammatory exudates. It is now widely
appreciated that miRNAs exert actions in the regulation of innate
and adaptive immune responses (Sonkoly and Pivarcsi, 2009;
Recchiuti et al., 2011). For example, miR-466l contains AU-rich
element (ARE) characteristic complementary sequences
(AUAAAUA) in the 50 seed region (Calabrese et al., 2007) and
upregulates interleukin-10 (IL-10) in macrophages (Ma et al.,
2010), as do SPMs (Recchiuti et al., 2011). Fungal infections
with Saccharomyces cerevisiae (S. cerevisiae) are increased in
immune-deficient patients and in patients who have experienced
trauma (Kyritsis et al., 2012; McCusker et al., 1994; Underhill
et al., 1999). Here, we studied zymosan (Zym) from
S. cerevisiae and monitored the initiation and resolution phases
in both resolving and delayed resolution (Bystrom et al., 2008;
Fredman et al., 2012). We report that miR-466l promoted both
initiation and resolution of inflammation, as well as macrophage
polarization via modulating select ARE-containing targets
(ARETs) and LM biosynthesis. Our findings indicate pivotal
role(s) for miR-466l-SPM regulatory networks and underscore
the dynamic plasticity of leukocytic exudates.mmunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc. 885
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Figure 1. Temporal and Differential Regulation of Exudate Leukocyte miR-466l during Self-limited versus Delayed Inflammation Resolution
Zym was injected (i.p.) for acute peritonitis into male FVB mice divided into three groups: high-dose (10 mg/mouse) challenged, low-dose (1 mg/mouse), and
RvD1-treated.
(A) Lavages were collected at indicated intervals, and PMNs were enumerated. See Experimental Procedures and Table S1 for the calculation of resolution
indices.
(B) Exudates from 1 and 10 mg of Zym-initiated murine peritonitis (0–48 hr) were collected for IL-10.
(C) Flow cytometry for apoptotic PMNs (Ly6G+AnxAV+).
(D) Flow cytometry for efferocytosis (F4/80+Ly6G+).
(E) Total RNAs were isolated at the indicated intervals, and expression of miR-466l was assessed by quantitative PCR (qPCR).
(F) miR-466l expression in each group at 24 hr.
(G and H) Quantitative expression of miR-466l in FACS-sorted PMNs (G), monocytes, and macrophages (H) from murine exudates. Results are expressed as
mean ± SEM from at least four independent experiments for each point in each panel. *p < 0.05, **p < 0.01, and ***p < 0.001 versus low-dose group.
See also Figure S1 and Table S1.
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miR-466l Is Temporally Regulated during Inflammation
Resolution
We soughtmechanisms governing SPMs in resolution and tissue
homeostasis. To this end, we employed a well-established
model of self-limited inflammation for differential comparison
with delayed resolution (Bannenberg et al., 2005; Fredman
et al., 2012) to address SPM-miR-466l interactions. Zym admin-
istered intraperitoneally (i.p.) at 1 mg per mouse elicited a self-
limited inflammatory response (Figure 1A). The resolution interval
(Ri) was 12 hr, and the self-resolving challenge was calculated
between maximal PMN infiltration and when PMN numbers
reduced by 50% (Figure 1A and Table S1, available online).
Monocytes and macrophages increased gradually and at 48 hr
were the majority of exudate leukocytes (Figure S1A). For com-
parison, high dosage led to a continued PMN increase until
48 hr, and at this juncture monocytes and macrophages were
37%. Excessive PMNs and limited monocyte andmacrophage
accumulation (Figure 1A and Figure S1A) affirmed that high
dosage resulted in delayed resolution and higher cytokines (Fig-886 Immunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc.ure 1B and Figures S1B–S1D). When RvD1 was given, a signifi-
cant decrease in PMN infiltration and monocytes was obtained.
This regulation of cellular trafficking by RvD1 promoted endoge-
nous proresolving programs that shortened resolution intervals
(Figure 1A and Table S1).
The apoptotic PMN number was significantly lower at 4 and
12 hr but higher at 24 hr in the 10 mg Zym group than in the
low-dose group (Figure 1C). RvD1 did not significantly affect
apoptosis of exudate PMNs. We also monitored macrophages
that efferocytosed apoptotic PMNs and found that efferocytosis
was lower at 4 and 12 hr in the 10mg Zym group than in the 1mg
Zym group (Figure 1D). These results indicate that exudate effer-
ocytosis by macrophages (Figure S1E) is higher in self-limited
resolution than in delayed resolution.
We monitored miR-466l expression by quantitative real-time
PCR by using exogenous Caenorhabditis elegans miR-39
(cel-miR-39) to normalize expression between samples as in
Mitchell et al., 2008. With a 1 mg Zym challenge, exudate
miR-466l markedly increased at 4 hr, most likely representing
the PMN content of these exudates, and subsequently
decreased sharply at 12 hr (Figure 1E); afterward, it increased
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RvD1 reduced miR-466l (Figures 1E and 1F). The amount of
miR-466l was 54% lower at 4 hr but 183% higher at 24 hr
in self-resolving exudates than in delayed-resolving exudates
(Figures 1E and 1F). To further address the cellular sources of
miR-466l during peritonitis, we employed fluorescence-acti-
vated cell sorting (FACS) to isolate exudate PMNs, monocytes,
and macrophages for miR-466l assessment. In the 1 mg Zym
group,miR-466l was highest in PMNs at 4 hr and then decreased
sharply. Subsequently, miR-466l increased slightly at 24 hr
(Figure 1G). miR-466l in monocytes and macrophages did not
significantly change at either 4 or 12 hr but did show a tendency
to increase at 24 hr (Figure 1H). The 10 mg Zym challenge
enhanced miR-466l accumulation in PMNs, monocytes, and
macrophages at 4 hr while reducing miR-466l in PMNs at
24 hr. Consistent with in vitro results (see below), RvD1 lowered
miR-466l in PMNs at 4 and 24 hr, as well as in monocytes and
macrophages at 24 hr (Figures 1G and 1H). Together, these
results indicate a correlation among PMN apoptosis, clearance
of apoptotic cells, and miR-466l, which is temporally and differ-
entially regulated.
miR-466l Regulates Inflammation Resolution
To investigate the actions of miR-466l in inflammation resolution,
we performed in vivo transfection in mice and determined the
regulation of leukocyte responses bymiR-466l with a self-limited
challenge. Here, we investigated the dynamic expression ofmiR-
466l in exudate leukocytes and found that miR-466l was upregu-
lated at 4, 24, and 48 hr (Figure 2A). PMN infiltration peaked at
12 hr in both groups. The maximal PMN number was signifi-
cantly higher in miR-466l-overexpressing murine peritoneal
macrophages than in those transfected with a vector control
(VC) (Figure 2B). Although miR-466l overexpression did not
shorten Ri, exudate PMNs decreased faster and reached lower
amounts at 48 hr (Figures 2B and 2C). To further quantify this,
we used the parameter K50, which is the rate of PMN reduction
from Tmax to T50. K50 of the miR-466l overexpression group
was 1.2 3 106 cells/hr, 2.2-fold faster than that of the VCs
(Figure 2C). Of note, overexpression of miR-466l in mice did
not significantly change the number of apoptotic PMNs in exu-
dates (Figure S2B), whereas it promoted efferocytosis during
both the initiation and the resolution phases (Figure 2D). With
cell sorting, we found that miR-466l was increased in PMNs at
4 hr and in monocytes and macrophages at 12 and 24 hr in
miR-466l-overexpressing exudates (Figures 2E and 2F; over-
expression of both miR-466l and GFP was controlled by the
same promoter in vivo [see Supplemental Experimental Proce-
dures]). To investigate the role of miR-466l in regulating PMN
responses during initiation of self-limited inflammation, we over-
expressed miR-466l in murine bone marrow neutrophils (BMNs)
and assessed the expression of both proinflammatory and
proresolving cytokines (Figures S2E–S2G). Overexpression of
miR-466l in BMNs enhanced the expression of interleukin-1b
(IL-1b), tumor necrosis factor a (TNF-a), and IL-10 (Figure S2E)
and increased chemotaxis to C5a (Figure S2F). Overexpression
of miR-466l in BMNs did not significantly stimulate intracellular
reactive oxygen species (ROS), whereas it increased TNF-
a-stimulated ROS (Figure S2G). To address the impact of neutro-
phil-associated miR-466l, we performed an adoptive transferIwith miR-466l-transfected BMNs and a subsequent challenge
(Figure 2H). In these, we found a significantly increased PMN
influx at 12 hr, suggesting that miR-466l overexpression gives
heightened PMN responses and promotes a proinflammatory
PMN phenotype in vivo within the initiation phase.
To address the role of miR-466l in regulating macrophage
responses during the initiation phase, we transfected murine
peritoneal resident macrophages with either an empty VC or
miR-466l ex vivo and carried out adoptive transfer (i.p.) prior to
challenge (Figures 2I and 2J and Figures S2H and S2I). In mice
that received miR-466l-overexpressing cells, we found a
significant reduction in PMNs recruited to the peritoneum in
response to challenge. Next, we assessedmiR-466l in regulating
macrophage responses during the resolution phase. To this end,
we performed adoptive transfer of peritoneal macrophages with
VC or miR-466l via intraperitoneal injection 12 hr after challenge
at the peak of inflammation. After 24 hr, we observed significantly
fewer exudate PMNs in mice that received miR-466l-
overexpressing macrophages than in mice that received either
VC-transfected macrophages or vehicle (Figure 2I); we also
obtained significant increases in macrophage efferocytosis at
24 hr (Figure S2I). In addition, injection of macrophages with
VC decreased Ri from 12 to 10 hr, and macrophages overex-
pressingmiR-466l further reducedRi to 8 hr (Figure 2J), indicating
that miR-466l expression in macrophages promotes a prore-
solving phenotype.
miR-466l Upregulates ARETs
Using high-throughput human genome BLAST homology search
and quantitative PCR, we identified expression of mature
miR-466l in human PMNs, monocytes, and macrophages (Fig-
ure S3A-E). To elucidate mechanisms by which miR-466l regu-
lates inflammation resolution, we assessed gene expression
profiling by using an inflammation-related genome-wide expres-
sion array in humanmacrophages after miR-466l overexpression
or silencing (Figure S3F). Overexpression of miR-466l upregu-
lated several ARET genes, e.g., those encoding IL-26 and
IL-1b. In addition, RNA-binding proteins, including cytotoxic
granule-associated RNA-binding protein (TIA1) (Asirvatham
et al., 2009) and fragile-X-mental-retardation-related protein 1
(FXR1) (Vasudevan and Steitz, 2007; Vasudevan et al., 2007),
which are predicted targets for miR-466l (Table S2), were signif-
icantly enhanced by miR-466l overexpression and reduced by
silencing, whereas mRNAs encoding tristetraprolin (TTP) and
human antigen R (HuR) (Asirvatham et al., 2009) were not mark-
edly changed (Figure S3F). Overexpression of miR-466l also
elevated KH-type splicing regulatory protein (KSRP) (Briata
et al., 2011), an RNA-binding protein without complementary
ARE sequences in the miR-466l seed region. Moreover, miR-
466l overexpression increased expression of select ARETs,
including CD18, FXR1, IL-10, and TNF-a (Figures S3G and S3H).
COX-2, a key enzyme in LM biosynthesis, has complementary
AREs in its 30 UTR (Table S2) and was increased by miR-466l
overexpression (Figure S3F). Using luciferase reporters, we
found that overexpression of miR-466l in macrophages
increased luciferase activity of the COX-2 30 UTR, but not the
COX-1 30 UTR (Figure S3I). Overexpression of miR-466l
enhanced 30 UTR stability of another ARET, transcriptional factor
nuclear factor kB1 (NF-kB1), an action that was lost when the 30mmunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc. 887
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Figure 2. Overexpression of miR-466l in Murine Leukocyte Exudates Regulates Acute Inflammation Resolution
(A–F)Male FVBmice were transfectedwith VC ormiR-466l and then challengedwith 1mg Zym (i.p.) for acute peritonitis. Peritoneal exudates were obtained at the
indicated intervals. Results are expressed as mean ± SEM from four independent experiments for each point. *p < 0.05 and **p < 0.01, miR466l versus VC. (A)
miR-466l expression was assessed with qPCR. (B) Infiltrated PMNs were enumerated. (C) Resolution indices for VC and miR-466l groups (see Experimental
Procedures). (D) Flow cytometry for efferocytosis (F4/80+Ly6G+). (E and F) Quantitative expression of miR-466l with FACS-sorted murine exudate PMNs (E) and
monocytes and macrophages (Mac) (F).
(G) Expression of GFP with murine exudate PMNs, monocytes, and macrophages from miR-466l-overexpressing mice. Results are expressed in median
fluorescence intensities (MFIs) asmean ± SEM from three independent experiments for each point. *p < 0.05, PMNs at 4 versus 24 hr; **p < 0.01, PMNs at 4 versus
12 hr; ##p < 0.01, monocytes and macrophages at 4 versus 24 hr.
(H) VC- and miR-466l-transfected murine BMNs (3 3 106/mouse) were injected into murine tail vein 5 min prior to intraperitoneal challenge with 1 mg Zym.
Peritoneal PMN numbers were counted at 4 or 12 hr. Results are expressed asmean ± SEM from at least three independent experiments for each point. yp < 0.05,
versus vehicle (Veh; saline); *p < 0.05, versus VC.
(I) VC ormiR-466l murine peritoneal macrophages (7.53 104/mouse) were transferred i.p. intomice 5min prior to or 12 hr after intraperitoneal challengewith 1mg
Zym. Peritoneal PMNs were counted at 12 hr (before challenge) or 24 hr (after challenge). Results are expressed as mean ± SEM from at least three independent
experiments for each point. yp < 0.05, versus Veh (saline); *p < 0.05, versus VC.
(J) Mice were injected i.p. with Veh (saline), VC, or miR-466l-overexpressing macrophages (7.5 3 104/mouse) 12 hr after Zym intraperitoneal challenge for
calculation of resolution intervals. Results are expressed as mean ± SEM from at least three independent experiments for each point.
See also Figure S2.
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miR-466l upregulates ARETs by stabilizing the 30 UTR of targets.
miR-466l Mediates Resolution-Phase Macrophage
Polarization
We next questioned whether miR-466l also regulates macro-
phage plasticity. Using multicolor immunofluorescence staining888 Immunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc.and flow cytometry, we found that markers associated with M1
macrophages—iNOS (1,064 ± 47 versus 389 ± 11 median fluo-
rescence intensity [MFI]), COX-2 (1,695 ± 169 versus 1,339 ±
290 MFI), and CD11c (1,066 ± 44 versus 787 ± 78 MFI)—were
upregulated in human macrophages overexpressing miR-466l
(Figure 3A and Figure S3F). miR-466l overexpression also
upregulated expression of M2 macrophage markers—CD206
AB
Figure 3. miR-466l Mediates Resolution-Phase Macrophage Polarization
(A) M1 and M2 macrophages were obtained from human peripheral-blood mononuclear cells. VC and miR-466l were transfected into human macrophages for
72 hr (37C). Phenotypeswere assessed by flow cytometry after multicolor staining with fluorescent-conjugated antibodies. Relative fluorescence units (RFU) are
normalized against VC and expressed as mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, miR-466l versus VC.
(B) FVB mice were transfected with VC or miR-466l (48 hr) and then challenged with 1 mg Zym for 48 hr. Lavage peritoneal cells stained with three fluorescent-
conjugated antibodies were analyzed by flow cytometry analysis. Representative flow cytometry histograms are shown. RFU are normalized against VC and
expressed as mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, versus VC.
See also Figure S3 and Table S2.
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miR-466l Regulates Inflammation Resolution(1,146 ± 129 versus 216 ± 33 MFI), ARG1 (1,420 ± 171 versus
1,027 ± 5 MFI), and 15-LOX-1 (1,173 ± 80 versus 790 ± 10
MFI)—as well as the resolution-phase macrophage markers
TIMD4 (2,612 ± 317 versus 797 ± 1MFI), HLA-DR (26 ± 11 versus
21 ± 8 MFI), and TGFb2 (1,163 ± 45 versus 288 ± 36 MFI). These
results are consistent with those obtained with murine peritoneal
monocytes and macrophages at 48 hr (Figure 3B) and together
indicate that miR-466l mediates polarization to a resolution-
phasemacrophage phenotype (Stables et al., 2011) with charac-
teristics of both classic M1 and M2 lineages.
miR-466l Regulates LM Biosynthesis
Using LM metabololipidomics, we identified and profiled SPMs,
including LXA4, RvD1, and RvD5, as well as proinflammatory
LMs (Figures 4). LM amounts were determined by multiple-reac-
tion monitoring, where overexpression of miR-466l in human
macrophages gave elevated prostaglandins (PGs) (PGE2 >
PGD2 > PGF2a) and SPMs (RvD2 > RvD5 > RvD1) (Figure 4D
and Table S3A). In exudates, overexpression of miR-466l led to
a significant upregulation of COX products (PGE2 > PGD2 >
PGF2a) and SPMs (RvD1 > PD1 > RvD5 > MaR1) (Table S3B).
LTB4 was not increased by miR-466l in either human macro-
phages or peritonitis exudates (Figure 4D, Table S3). Hence,
miR-466l facilitates PG and SPM biosynthesis during acute
inflammation resolution.
miR-466l Enhances Macrophage Chemotaxis and
Phagocytosis by Increasing SPM Production
Given that successful clearance of pathogens and apoptotic
cells relies on efficient leukocyte migration into the infectious
site, we investigated the regulation of macrophage chemotaxis
by miR-466l with C5a, a classic chemoattractant (Gallin and
Gallin, 1977), and ATP, a molecule that is released from dying
cells as a ‘‘find-me signal’’ (Elliott et al., 2009). Overexpression
of miR-466l significantly enhanced human macrophage chemo-
taxis to both C5a and ATP (Figures 5A and 5B). We did not
observe differences inmacrophage accumulation in the absence
of a chemoattractant. miR-466l also enhanced macrophage
chemotaxis to other agonists (Figure S4). Silencing of miR-466l
inhibited macrophage chemotaxis to several chemoattractants
(Figures 5A and 5B and Figure S4). miR-466l overexpression
enhanced macrophage efferocytosis of apoptotic PMNs (Fig-
ure 5C), an action inhibited by cytochalasin B (Figure 5D), indi-
cating that miR-466l enhances macrophage chemotaxis and
phagocytosis by promoting contractile microfilament formation.
We next questioned whether LMs play a role in mediating
phagocytic actions of miR-466l. Incubations of miR-466l-trans-
fected macrophages with a LOX inhibitor (baicalein) led to a
reduction in efferocytosis of apoptotic PMNs, whereas RvD1 or
a COX inhibitor (indomethacin) significantly increased efferocy-
tosis (Figure 5E), in line with published results (Sadik et al.,
2003; Schwab et al., 2007; Yamada and Suzuki, 1989). These
findings demonstrate that miR-466l stimulates macrophage
efferocytosis in a LOX-dependent manner. Consistent with
earlier findings with human PMNs (Levy et al., 2001), exposure
of macrophages to COX products PGD2 and PGE2 for 18 hr
significantly upregulated expression of 15-LOX-1 (Figure 5F),
an enzyme involved in SPMproduction. Amounts of chemotaxis-
and phagocytosis-associated proteins, including purinoceptor890 Immunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc.P2Y2 (Elliott et al., 2009), MER tyrosine protein kinase (MERTK)
(Scott et al., 2001), and thrombospondin 1 (THBS1) (Savill
et al., 1992), were increased by miR-466l overexpression and
RvD1 (Figures 5G–5I and Figure S3F). LOX inhibitor down-
regulated these, an action partially rescued by RvD1 (Figures
5G–5I), suggesting that SPMs act with miR-466l to upregulate
chemotaxis- and phagocytosis-associated pathways.
SPMs Regulate miR-466l in Human Leukocytes and Its
Identification in Sepsis Patients
With human PMNs and macrophages, Zym dose-dependently
increased miR-466l expression (Figure S5A), whereas RvD1,
RvD2, and MaR1 (10 nM) each reduced miR-466l (Figures 6A
and 6B). In addition, SPMs significantly counterregulated Zym-
stimulated miR-466l expression in both cell types, consistent
with in vivo findings with murine exudates (Figure 1). Apoptotic
PMNs are potent activators of resolution given that macrophage
efferocytosis of apoptotic PMNs results in the release of anti-
inflammatory cytokines (e.g., TGFb1 and IL-10) and the biosyn-
thesis of SPMs, including RvE1, PD1, and LXA4 (Dalli and
Serhan, 2012; Freire-de-Lima et al., 2000; Schwab et al.,
2007). Similar to RvD1, apoptotic PMNs decreased miR-466l in
human primary macrophages (Figures 6C and 6D). These results
establish that expression of miR-466l in human primary leuko-
cytes is regulated by proresolving signals, e.g., SPMs and
apoptotic PMNs.
We assessed dynamic expression of miR-466l during apo-
ptosis of human PMNs and found that miR-466l was not reduced
after 0–12 hr but that it was reduced at 48 hr (>85% of PMNs
were apoptotic). Zym delayed PMN apoptosis, whereas
serum-treated (opsonized) Zym (STZ) incubation promoted
PMN apoptosis (Figure 6E). With Zym, miR-466l accumulated
at 4 hr but subsequently reduced at 12 and 48 hr. As expected,
STZ reduced miR-466l at 4 and 12 hr yet increased miR-466l at
48 hr (Figure 6E), suggesting that spontaneous apoptotic PMNs
and phagocytosis-induced apoptotic PMNs give distinct
miR-466l profiles.
In order to assess the potential of miR-466l in disease, we
examined the expression of this miRNA in peripheral whole
blood and plasma obtained from intensive care unit (ICU)
patients with confirmed Escherichia coli (E. coli) sepsis and
from ICU patients without sepsis (control). Samples were
collected upon ICU admission, denoted ‘‘day 0’’ (defined as
blood collection within 48 hr of ICU admission), and then on
days 3 and 7 of the patients’ hospital stay. Sepsis patients
were divided into those in whom sepsis resolved during hospital-
ization (sepsis survivors) and those who suffered in-hospital
mortality (sepsis nonsurvivors) (Table S4). Real-time PCR results
demonstrated that on day 0, miR-466l expression in whole blood
of sepsis survivors was significantly higher than that in nonseptic
ICU subjects (Figure 6F). miR-466l expression was downregu-
lated in whole-blood samples from sepsis survivors on days 3
and 7. Assessment of plasma miR-466l demonstrated no signif-
icant differences between sepsis survivors and nonseptic ICU
patients on day 0 (Figure 6F). Also, we found a reduction in
plasma miR-466l on both day 3 and day 7 compared to day 0.
Compared to both nonseptic ICU patients and sepsis survivors,
sepsis nonsurvivors showed a significant increase in bothwhole-
blood and plasma miR-466l on day 0 (Figure 6F). Whole-blood
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Figure 4. Macrophage LM Profiles Are Regulated by miR-466l
Humanmacrophages transfected with VC,miR-466l, anti-miRNA-neg, or anti-miR-466l were washed with PBS twice and incubated with Zym (100 ng/ml) for 4 hr.
For terminating incubations, ice-cold MeOH was added and samples were subjected to solid-phase extraction. LMs were identified and quantified by LC-MS/
MS-based LM metabololipidomics.
(A) Representativemultiple-reactionmonitoring chromatograms (from three independent experiments) show the elution times for the identified bioactive LMs: Q1,
M-H (parent ion); and Q3, diagnostic ion in the tandem mass spectrometry (MS/MS) (daughter ion).
(B) MS/MS spectrum employed for the identification of PGD2.
(C) MS/MS spectrum employed for the identification of RvD5.
(D) Quantification of arachidonic-acid- and docosahexaenoic-acid-derived LMswas obtained with a calibration curve for each compound. Results are expressed
as mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, versus VC; #p < 0.05, versus anti-miRNA-neg.
See also Table S3.
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Figure 5. Macrophage Chemotaxis and Efferocytosis Are Enhanced by SPMs and miR-466l
(A–C) Humanmacrophageswere transfectedwith VC,miR-466l, anti-miRNA-neg, or anti-miR-466l (37C, 72 hr). Chemotaxis dose response to C5a (A) or ATP (B)
is shown. (C) Efferocytosis of apoptotic PMNs (1:3). Results were normalized as fold change of VC or anti-miRNA-neg and expressed asmean ± SEM from at least
four independent experiments. *p < 0.05 and **p < 0.01, versus VC; #p < 0.05 and ##p < 0.01, versus anti-miRNA-neg.
(D) VC- and miR-466l-transfected human macrophages were treated with cytochalasin B (CB, 1 mg/ml) for 1 hr and incubated with apoptotic PMNs (1:3) for 1 hr.
Efferocytosis was assessed with flow cytometry. Results are expressed as mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, versus VC;
##p < 0.01, versus miR-466l.
(E) VC- andmiR-466l-transfected humanmacrophages were pretreated with PBS (Veh), 10 nMRvD1, 10 mMbaicalein (Bai), 10 nMRvD1 plus 10 mMBai, or 10 mM
indomethacin (Indo) for 1 hr and then incubated with apoptotic PMNs (1:3) for 1 hr. Efferocytosis was assessed with flow cytometry. Results are expressed as
mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, versus VC Veh; zp < 0.05, versus VC plus Bai; xxp < 0.01, versus VC plus Indo; #p < 0.05
and ##p < 0.01, versus miR-466l Veh; &p < 0.05, versus miR-466l plus RvD1; {p < 0.05, versus miR-466l plus Bai.
(F) Human macrophages were incubated with PGD2 (1 mM), PGE2 (1 mM), or PGD2 plus PGE2 (1 mM each) for 18 hr. Total RNA was isolated, and 15-LOX-1
expression was assessed with flow cytometry. Results are expressed as mean ± SEM from four independent experiments. *p < 0.05 and **p < 0.01, versus Veh;
yp < 0.05, versus PGD2;
zp < 0.05, versus PGE2.
(G–I) VC- and miR-466l-transfected human macrophages were treated with PBS (Veh ), 10 nM RvD1, 10 mM Bai, or 10 mM Bai plus 10 nM RvD1 for 18 hr.
Expression levels of P2Y2 (G), MERTK (H), and THBS1 (I) were assessed with flow cytometry. Results are expressed as mean ± SEM from four independent
experiments. *p < 0.05 and **p < 0.01, versus VC Veh; yyp < 0.01, versus VC plus RvD1; zp < 0.05 and zzp < 0.01, versus VC plus Bai; Vp < 0.05, versus VC plus Bai
plus RvD1; #p < 0.05 and ##p < 0.01, versus miR-466l Veh; &p < 0.05, versus miR-466l plus RvD1; {p < 0.05, versus miR-466l plus Bai.
See also Figure S4.
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Figure 6. SPMs Regulate miR-466l in Human Leukocytes and Its Identification in Sepsis Patients
(A and B) Human PMNs (106 cells/ml) (A) andmacrophages (106 cells/ml) (B) were incubated with or without Zym (10 ng/ml) (Veh) and 10 nM of SPM (RvD1, RvD2,
or MaR1) for 4 hr (PMNs) or 18 hr (macrophages). Expression of miR-466l was assessed by qPCR. Results are expressed as mean ± SEM from five independent
experiments. *p < 0.05 and **p < 0.01, versus Veh control (PBS); #p < 0.05, versus Zym alone.
(C) Humanmacrophages (106 cells/ml) were incubated with PBS (Veh), RvD1 (10 nM), and/or apoptotic PMNs (1:3) for 2, 4, and 18 hr, and expression of miR-466l
was assessed by qPCR. Results are normalized as fold change of vehicle.
(D)NormalizedmiR-466l at 4 hr posttreatment is expressedasmean±SEM from four independent experiments. *p<0.05, versusVeh; yp<0.05, versusRvD1group.
(E) Human PMNs were incubated with PBS, Zym (10 ng/ml), or STZ (opsonized Zym, 10 ng/ml) for 0–48 hr. Apoptosis (% AnxA V+ PMNs) was assessed by flow
cytometry (top inset, right). miR-466l expression was assessed by qPCR. Results are expressed as mean ± SEM from three independent experiments. *p < 0.05
and **p < 0.01, versus Veh control (PBS).
(F) Peripheral blood and plasma were collected from nonseptic ICU control patients (nonseptic survivors), E. coli sepsis patients who survived, and nonsurvivors
of E. coli sepsis on day 0 of ICU admission (within 48 hr of ICU admission). See Table S4 for a description of patients. Total RNAwas isolated from peripheral blood
and plasma, and quantitative miR-466l expression was expressed as mean ± SEM of three patients in each group. *p < 0.05, versus nonseptic ICU patients; #p <
0.05, versus sepsis patients.
See also Figure S5 and Table S4.
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also significantly lower than day 0 values. A similar trend was
found with plasma miR-466l on days 3 and 7. Also, we noted
that the percentage of miR-466l in plasma was lower in sepsis
nonsurvivors than in sepsis survivors and nonseptic ICU sub-
jects on day 0, suggesting that increasedmiR-466l in sepsis non-
survivors’ blood on day 0 was mostly cell associated.
In these patients, C-reactive protein (CRP), creatinine, IL-1b,
IL-6, IL-18, and procalcitonin (PCT) were each increased in
sepsis plasma; IL-18 values were statistically significantly
higher in the plasma of sepsis nonsurvivors than in the plasma
of ICU controls (Table S5 and Figure S5B). This is in line with
recent findings that peripheral-blood IL-18 correlates with
nonsurvivors of sepsis-induced acute respiratory-distress syn-
drome (Dolinay et al., 2012). Together, these results indicate
that miR-466l is differentially regulated in human peripheral
blood during sepsis and that elevation in circulating miR-466l
correlates with sepsis nonsurvivors. Hence, in view of ourIresults with murine inflammatory exudates (Figures 1 and 2),
these results with sepsis patients suggest that peripheral-blood
miR-466l might correlate with an excessive inflammatory
phenotype.
AP-1 and NF-kB1 Contribute to SPM-miR-466l
Regulatory Networks
Several transcription factors (TFs) are also ARETs, among which
are activator protein 1 (AP-1, whose family includes c-Jun and
c-Fos) and nuclear factor kB1 (NF-kB1); these ARETs and their
phosphorylation were upregulated by miR-466l overexpression
(Figures S4A and 7A). We investigated the underlying signaling
involved in SPM counterregulation of Zym-stimulated miR-
466l. Humanmacrophages with Zym led to a significant increase
in p-JNK, p-p38-AP-1, and IkB-NF-kB1 signals, which were
reduced by RvD1, RvD2, and MaR1 (Figures 7B and 7C). Of
note, LXA4 inhibits AP-1 and NF-kB activation in PMNs (Jo´zsef
et al., 2002).mmunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc. 893
Figure 7. AP-1 and NF-kB1 Contribute to SPM-miR-466l Regulatory Networks
(A) Humanmacrophages were transfected with VC, miR-466l, anti-miRNA-neg, or anti-miR-466l for 72 hr. Total proteins were isolated for IkBa, p-NF-kB, p-JNK,
and p-p38 ELISA (miR-466l overexpression [OE]; miR-466l silencing [Si]). Results are normalized against VC or anti-miRNA-neg and expressed as mean ± SEM
from four independent experiments. *p < 0.05, versus VC; #p < 0.05, versus anti-miRNA-neg.
(B andC) Humanmacrophageswere exposed to Zym (10 ng/ml) and/or SPM (RvD1, RvD2, orMaR1 [10 nM each]) (37C, 18 hr, pH 7.45). (B) Protein expression of
p-JNK, p-p38, IkBa, and NF-kB, and (C) mRNA values of c-Jun and NF-kB1were assessedwith ELISA and qPCR, respectively. Results are expressed asmean ±
SEM from five independent experiments. *p < 0.05 and **p < 0.01, versus Veh control; #p < 0.05 and ##p < 0.01, versus Zym alone.
(D) Humanmacrophages were transfected with shAP-1, shNF-kB1, or shscrambled (sh-neg) for 48 hr. Expression levels of miRNA-biogenesis-associated genes,
pri-miR-466l, pre-miR-466l, miR-466l, and select resolution-related miRNAs were determined with qPCR. Heatmap results were normalized with sh-neg as
controls and are expressed as the mean of five independent experiments.
(E) Human macrophages were preincubated with PTX (100 ng/ml) for 24 hr (37C, pH 7.45) and then treated with RvD1, RvD2, or MaR1 (10 nM each) for 18 hr
(37C, pH 7.45); expression levels of miR-466l, c-Jun, NF-kB1, TNFa, COX-2, and TLR4 were assessed by qPCR. Heatmap results were normalized against VC
and are expressed as themean of five independent experiments. The results of NF-kB1 and TNFa are expressed asmean ± SEM. *p < 0.05 and **p < 0.01, versus
Veh control; #p < 0.05, versus RvD1 Veg; yp < 0.05, versus RvD2 Veg; zp < 0.05 and zzp < 0.01, versus MaR1 Veg.
See also Figure S6.
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miR-466l Regulates Inflammation ResolutionEmploying VISTA software (Frazer et al., 2004), we found that
the promoters of miRNA-biogenesis-associated genes (Bartel,
2009), including those encoding exportin 5 (XPO5), Dicer1, and894 Immunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc.transactivation-responsive RNA-binding protein 2 (TRBP2),
contain binding sites for AP-1, whereas KSRP (Briata et al.,
2011), TRBP2, and argonaute-2 (Ago2) are predicted to be
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miR-466l Regulates Inflammation ResolutionNF-kB1 targets (Figure S6). In Figure 7D (left panel), a heatmap
depicts that AP-1 or NF-kB1 silencing decreased amounts of
Drosha and Dicer1. Amounts of both Ago2 and KSRP were
also reduced by NF-kB1 RNAi, and AP-1 silencing decreased
XPO5 and TRBP2. We next investigated whether inhibition of
either AP-1 or NF-kB1 would regulate miR-466l biogenesis and
found that inhibition of either in human macrophages led to a
significant reduction in precursor miR-466l (pre-miR-466l) and
mature miR-466l1 expression, but not in primary miR-466l
(pri-miR-466l) expression (Figure 7D, right panel). These results
suggest that AP-1 and NF-kB1 promote miR-466l expression
in human macrophages by enhancing the maturation process.
Inhibition of AP-1 andNF-kB1 also led to downregulation of other
resolution-related miRNAs (Recchiuti et al., 2011), including
miR-146b, miR-208, and miR-219-2-3p (Figure 7D, right panel).
These results demonstrate that AP-1 and NF-kB1 promote the
biogenesis of resolution-associated miRNAs.
SPMs activate resolution and display their anti-inflammatory
and proresolving actions via G-protein-coupled receptors
(GPCRs) (Recchiuti et al., 2011; Serhan, 2007). The amounts of
these GPCRs (i.e., LXA4 receptor [ALX-PR2], RvD1 receptor
[DRV1 or GPR32], and RvE1 receptor [ERV1] or chemerin recep-
tor 23 [ChemR23]) were not increased by miR-466l overexpres-
sion in human macrophages, but amounts of both DRV1 and
ERV1 were decreased by miR-466l silencing (Figure S4A).
RvD1, RvD2, and MaR1 actions on miR-466l pathway genes,
including those encoding AP-1, NF-kB1, TNFa, COX-2, and
TLR4, were blocked by pertussis toxin (PTX) (Figure 7E).
DISCUSSION
Here, we have reported that miR-466l is regulated by Zym and
counterregulated by SPMs in human leukocytes and murine
inflammatory exudates. Using resolution indices, we first estab-
lished that (Bannenberg et al., 2005) miR-466l is dynamically
regulated during self-limited inflammation in mice and present
in peripheral blood of sepsis patients. Overexpression of miR-
466l in mice enhanced leukocytic infiltration, regulated exudate
leukocyte plasticity, and elevated SPM biosynthesis, thus accel-
erating clearance of apoptotic PMNs. These findings indicate
that miR-466l and SPMs are pivotal in governing the advance-
ment to resolution.
During the resolution phase of the inflammatory response,
there is a shift in the leukocyte composition of the inflammatory
exudates and a nonphlogistic accumulation of monocytes and
macrophages at later time intervals (Serhan and Savill, 2005).
In resolving exudates, the main cellular sources of miR-466l
are monocytes and macrophages. Hence, miR-466l expression
is temporal in that miR-466l is carried with PMN traffic influx to
the inflammatory site during initiation and with monocytes and
macrophages during resolution, thus dictating the impact of
miR-466l in initiation versus programmed resolution. Along these
lines, overexpression of miR-466l in murine BMNs increased the
amounts of IL-1b, TNF-a, and IL-10, accelerated chemotaxis to
C5a and TNFa, and increased ROS production. Injection of miR-
466l-transfected BMNs prior to Zym significantly enhanced PMN
infiltration at 12 hr. In addition, adoptive transfer of murine peri-
toneal macrophages overexpressing miR-466l prior to challenge
or at the peak of inflammation led to significant reductions inIPMN infiltration, shortening the Ri. These results indicate that
miR-466l in monocytes and macrophages promotes a prore-
solving phenotype that facilitates resolution.
Sepsis ICU patients have elevated proinflammatory mediators
(Dolinay et al., 2012). The amount of miR-466l in peripheral blood
obtained from ICU patients with E. coli sepsis was higher in
sepsis nonsurvivors than in survivors. We also found with human
leukocytes that miR-466l was regulated in a dose-dependent
manner after exposure to stimuli. These findings are consistent
with the fact that high-dose challenge gave higher amounts of
miR-466l in the initiation phase of murine peritonitis than in
self-limited inflammation. Thus, together these findings suggest
that miR-466l reflects inflammatory status.
LM biosynthesis is temporal during initiation and resolution
(Serhan 2007) such that after a self-limited challenge, both
leukotrienes and PGs peak during the initiation phase
(4–12 hr) and subsequently decline in the resolution phase. In
these settings, accumulation of RvD1, RvD2, and RvD5
reached a maximum (amounts known to be bioactive) at the
early stage in the resolution phase (Dalli and Serhan, 2012;
Fredman et al., 2012). In the present report, miR-466l overex-
pression promoted RvD1 biosynthesis by upregulating 15-
LOX-1 in human macrophages; 15-LOX-1 is a key enzyme for
initiating D-series resolvin and protectin production (Dalli and
Serhan, 2012). In line with these, miR-466l accumulated early
in self-limited inflammation, and its overexpression stimulated
an increase in RvD1 in murine inflammatory exudates. Given
that in these experimental settings PMNs did not express 12/
15-LOX, the murine ortholog of human 15-LOX-1 (Levy et al.,
2001), these results suggest that miR-466l expression in mac-
rophages promotes RvD1 biosynthesis, which in turn regulates
exudate dissolution. This enhanced biosynthesis of proresolv-
ing mediators during the early stages of an inflammatory
response is in line with earlier results on the proresolving
functions of these mediators, namely stopping further PMN
infiltration, stimulating PMN apoptosis (El Kebir et al., 2012)
and macrophage efferocytosis, and shortening Ri (Serhan
2007; Serhan and Savill 2005).
In general, miRNAs regulate protein expression by inducing
target mRNA degradation or repressing translation. miR-466l
was identified in murine embryonic stem cells, macrophages,
spleen, and lymph nodes (cf. Calabrese et al., 2007; Chiang
et al., 2010) and was found to upregulate IL-10 in murine macro-
phages (Ma et al., 2010). A hypothesized mechanism via miR-
466l antagonizes TTP binding to IL-10 AREs, resulting in reduced
IL-10 mRNA decay and relative upregulation (Ma et al., 2010). In
the present study, expression profiling of a potential miR-466l
target gene indicated that miR-466l upregulated several ARETs,
including CD18, IL-10, and TNFa, each of which has comple-
mentary UAUUUAU in its 30 UTR. miR-466l increased 30 UTR
stability of COX-2 and NF-kB1 in macrophages. This is consis-
tent with recent results that specific miRNAs with AREs in the
50 seed region can switch target mRNA repression to activation
by increasing 30 UTR stability (Mortensen et al., 2011; Vasudevan
et al., 2007). Of note, COX-2 is a key enzyme in the production of
PGD2 and PGE2, mediators that are known to regulate the
expression of human 15-LOX-1 and thus promote lipid mediator
class switching during the resolution phase of inflammation
(Levy et al., 2001). In human macrophages, AP-1 and NF-kB1mmunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc. 895
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Because overexpression of miR-466l led to upregulation of
resolving macrophage-associated markers, e.g., COX-2,
15-LOX-1, TIMD4, and TGFb2, and an increase in SPM produc-
tion, our findings suggest that miR-466l regulates resolution by
upregulating SPM biosynthesis, which promotes a homeostatic
macrophage phenotype.
SPMs are now appreciated as regulators and markers of M1
and M2 phenotypes (Dalli and Serhan, 2012; Titos et al., 2011)
and play roles in both the onset and the resolution of inflamma-
tion (Rajakariar et al., 2006; Serhan and Savill, 2005). LM signa-
ture profiles have shown that M2 cells produce higher amounts
of SPMs, including MaR1, but that they produce lower LTB4-
and COX-derived LMs than do M1 cells (Dalli and Serhan,
2012). Using LC-MS/MS (liquid chromatography-tandem mass
spectrometry), we observed the elevation of PGs (e.g., PGD2
and PGE2 via COX-2) and SPMs (e.g., RvD1 and RvD5 from
15-LOX) in miR-466l-overexpressing macrophages. These
results demonstrate that miR-466l mediates resolution-phase
macrophage polarization.
In summation, the present results have established that
miR-466l is temporally and differentially expressed during
programmed resolution. miR-466l overexpression promotes
initiation in PMNs and accelerates resolution in macrophages.
In human leukocytes, miR-466l expression is downregulated
by resolution signals, including apoptotic PMNs, RvD1, RvD2,
and MaR1. Overexpression of miR-466l in macrophages skews
populations to a unique resolution-macrophage-like phenotype
(Bystrom et al., 2008; Sica and Mantovani, 2012; Stables et al.,
2011) that promotes resolution. These populations exhibit
enhanced chemotaxis and efferocytosis and upregulated SPM
biosynthesis. RvD1 also modulates miR-466l expression as a
potential negative feedback during inflammation resolution.
In sepsis patients, increased miR-466l correlates with non-
survival in sepsis. This miR-466l circuit displays pivotal roles in
acute inflammatory responses, as demonstrated in peritonitis
with regulatory networks involving RNA-binding proteins, TFs,
and SPMs. These signaling networks further delineate that reso-
lution actively begins with initiation of inflammation (Serhan and
Savill, 2005). Moreover, they provide a molecular basis for de-
layed resolvers and nonresolving phenotypes in humans (Morris
et al., 2010; Pillai et al., 2012). SPM local production and action
on leukocyte trafficking and function, as well as miRNA regula-
tion, can exert sustained tissue alterations that permit return to
homeostasis.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
RvD1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic
acid), RvD2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexae-
noic acid; validated according to published criteria, Dalli and Serhan,
2012), PGD2 (9a,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid),
PGE2 (9-oxo-11a,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid), and COX-2
monoclonal FITC antibody were obtained from Cayman Chemical. RvD5
used in these experiments was prepared as in Chiang et al., 2012; MaR1
(7R,14S-dihydrozy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid; Serhan
et al., 2012) was synthesized by Nicos A. Petasis (University of Southern
California, P01-GM095467 to C.N.S.). See Supplemental Information for
other reagents and chemicals, including real-time PCR primer sequences
(Table S5).896 Immunity 39, 885–898, November 14, 2013 ª2013 Elsevier Inc.miRNA Sequences, Targets, and Gene Nomenclature
The investigated miR-466l has been reported in accordance with the miRBase
registry gene annotation and nomenclature (http://www.mirbase.org/) or the
National Center for Biotechnology Information (NCBI) database. Targets for
miR-466l were obtained with TargetScan (http://www.targetscan.org/),
miRDB (http://mirdb.org/miRDB/), and miRanda (http://www.microrna.org/
microrna/home.do) with default parameters. The miRBase accession number
for mmu-miR-466l-3p is MIMAT0005830.
Murine Peritonitis Model and In Vivo Transfection
Murine peritonitis procedures were approved by the Standing Committee on
Animals of Harvard Medical School (protocol 02570) and performed in
accordance with institutional guidelines. Murine BMNs and peritoneal macro-
phage isolation, transfection, and injection are described in the Supplemental
Information. Resolution indices were calculated as defined in Schwab et al.,
2007 and are as follows:Jmax, themaximal PMNnumbers; Tmax, the time point
of maximal PMN infiltration; J50, 50% of maximal PMNs; T50, the time point
when PMN numbers reduced to 50% of the maximum; Ri (resolution interval,
T50 to Tmax), the time period when 50% of PMNs were lost from exudates; and
K50, the rate of PMN reduction from Tmax to T50.
Human Subjects
Survivors and nonsurvivors with E. coli sepsis were identified from our institu-
tional-review-board-approved Registry of Critical Illness (RoCI) (protocol
2008P000495, Brigham and Women’s Hospital [BWH]), in which subjects
were enrolled from the BWH ICUs within 48 hr of ICU admission and then
characterized as nonseptic ICU controls, sepsis survivors, or sepsis nonsurvi-
vors, as described previously (Dolinay et al., 2012; Nakahira et al., 2011; Sun
et al., 2012). Blood was collected upon enrollment (‘‘day 0’’) and on days 3
and 7 after hospitalization andwas stored (–80C) in PAXgene tubes (QIAGEN).
Plasma was isolated and stored (–80C) from subjects at the same time point.
miRNAs were obtained, and miR-466l was measured.
Preparation of Apoptotic PMNs, Leukocyte Functions, and LC-MS/
MS-Based Targeted LM Metabololipidomics
PMNs were isolated from fresh peripheral blood of healthy volunteers as
described (protocol 1999-P-001297, approved by the Partners Human
Research Committee, Boston). Fluorescently labeled apoptotic human
PMNs were obtained after overnight incubation in RPMI 1640 of freshly
isolated PMNs prelabeled with CFDA (10 mM; Sigma). Human macrophage
isolation, transfections, leukocyte functional assays (ROS, chemotaxis,
efferocytosis), and luciferase assays, as well as metabololipidomics, are
described in the Supplemental Information.
Statistical Analysis
All results are expressed as mean ± SEM. Statistical differences between
groups were compared with a Student’s t test or one-way ANOVA. p < 0.05
was considered statistically significant.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE52174.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
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